Hot Investor Mandate: Cross-Border Fund Seeks Global Opportunities in MedTech, Most Interested in CVD, Chronic Diseases, and More

30 Mar

A venture capital fund founded in 2015 and based in China closed its second fund at ¥100M that again focuses on opportunities in China. The firm invests in early-stage life science ventures from Seed to Series A. Typical initial size of investment ranges from $500k-1M USD.

The firm will consider medical devices especially minimally invasive medical devices, and diagnostics. Within medical devices, the fund is interested in 510k and software-enabled devices and looks at the in-development phase (must include proof of concept). Particularly, the firm is interested in devices related to digital technology such as artificial intelligence. Within diagnostics, the firm is interested in in-vitro diagnostics that are in-development. The main indication areas of interest are heart disease, infectious disease, chronic disease, and rehabilitation.

The firm prefers to work with a management team with established industry partners. The fund also prefers the CEO to have expertise in the respective life science fields. The fund is open to both leading and co-investing and will not require board seating. Although it has a China focus, the fund has supporting partners who are able to work with offshore companies that are interested in attaining proof of concept in China.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Investment Firm Actively Seeks Novel Medical Devices & Smart Manufacturing Technologies With Strong IP

30 Mar

A venture capital firm founded in 2016 and is headquartered in the USA. The firm currently manages 3 funds, and also has an advisory business that is solely dedicated for companies trying to enter the Asian market. The firm has a focus on early-stage investments (pre-Series A to Series B) and has portfolio companies spread over the USA. The firm’s initial investment size varies, but typically falls under the $250K – 2.5M range and is dedicated to follow-on financings of existing portfolio companies. The firm invests only in USA and Canada.

Within life sciences/healthcare, the firm is most interested in medical devices and smart manufacturing in life sciences, and is much more selective when it comes to biotech or therapeutics investments. Most importantly, the firm is focused on assessing the company’s patent status and the degree of novelty. While the firm is agnostic to stage of development, ideally the companies should have a working prototype and significant key data that validates the high potential of their technology. In terms of different types of technologies or diseases areas/indications, the firm is opportunistic.

The firm has no specific management team requirements, but considers patent strategy key in reviewing potential investments. Companies should have key patents issued or a clear strategy on improving their IP portfolio. The firm has great expertise in helping USA/Canada-based companies enter Asian markets (i.e. greater China) and extend their IP coverage. The firm can act as either lead or co-investor and will seek a board seat if they come in as a lead investor.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China-Based VC Firm With an Inaugural USD Fund Seeks Investment Opportunities in Therapeutics & Diagnostics Addressing Unmet Clinical Need

30 Mar

A venture capital firm founded in 2014 and based in China. The firm currently holds ¥3B in assets under management. Historically, the firm focused on investing only in China. However, the current fund of $300M USD is focused on opportunities in the United States. The firm invests in early-stage life science ventures from Seed to Series B. Typical initial size of investment ranges from $100k-5M USD.

The firm will consider cost-effective therapeutics and diagnostics that reach urgent and unmet clinical needs. Within therapeutics, the firm is interested in cell & gene therapy, gene editing, and organoids, and looks at pre-clinical to Phase III. Within diagnostics, the firm is open to all types of technologies and phases of development.

With an overarching focus on the aging population, the firm is interested in technologies that can improve the quality and longevity of life. The main indication areas of interest are neurological pathways, CNS, and chronic and acute pain management.

The firm does not have any requirements of the management team. Further down the road, the firm is able to support companies that are interested in entering the China market. However, having a China angle is not necessary for investment. The firm intends to act as a co-investor.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Congratulations to the IPC Winners, Next Up RESI Boston, June 5-7

22 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Congratulations to all Innovator’s Pitch Challenge (IPC) finalists that participated in Digital RESI March last week. During the 3-day virtual conference, 30+ pitch companies were featured on a dedicated landing page that hosted their supplementary materials and participated in a live Q&A session with a panel of judges, who are active investors or industry experts in the space. They presented their unique and innovative technologies and products to the RESI attendees, and these technologies and products represent the future of life science arena. RESI attendees voted for their favorite pitch companies. Congratulations to the three IPC winners!

1st Place

Recognized as the 2022 Top Emerging Company at BIO International, SiVEC Biotechnologies has developed BactPac™, a live biotherapeutic delivery platform to enable the next generation of nucleic acid and gene editing therapies. BactPac is engineered to produce therapeutic payloads (mRNA, siRNA, proteins, and CRISPR/Cas) and safely deliver these payloads to targeted tissues (e.g., pancreas, lungs, heart and brain) that cannot be targeted by viral vectors and lipid nanoparticles (LNPs). BactPac can generate large and varied therapeutic moieties that have applications in a wide range of disease indications, including cancer, genetic, infectious, and chronic diseases. Using the BactPac platform, SiVEC is developing a first-in-class therapeutic pipeline targeting a range of therapeutic areas, including oncology, respiratory diseases, and rare genetic diseases. SiVEC has secured nearly $4M in NIH SBIR funding, has a strong patent portfolio, and has an early collaboration with a gene-editing company. We are seeking a $7M seed investment.

Check Out SiVEC Biotechnologies’ Dedicated Page

2nd Place

Reglagene is a therapeutics company dedicated to developing transformational therapies for brain diseases. Reglagene’s product RGN6024 demonstrated proof of concept, safely shrinking tumors in a therapy resistant animal model of brain cancer and beating todays standard of care head-to-head. RGN6024 is the subject of a 2023 patent filing, has a concise manufacturing process, and a risk-mitigating, diversified clinical development plan. We anticipate the start of human clinical trials in mid 2024. Reglagene’s second product in development leverages what we’ve learned from RGN6024 biology to target diseases driven by neuroinflammation, such as Parkinson’s Disease.

Check Out Reglagene’s Dedicated Page

3rd Place

Amplified Sciences is a clinical stage life science in-vitro diagnostics company with an ultra-sensitive molecular-sensing platform technology with composition of matter IP exclusively licensed from Purdue University focused on accurately detecting debilitating diseases sooner. Their lead assay for early detection of pancreatic cancer is supported with clinical published data and provides increased accuracy and earlier detection helping gastroenterologists stratify patients at risk for pancreatic cancer. Open $3M Series Seed Preferred, led by OCA Ventures and Elevate Ventures will fund opening of clinical lab, CLIA regulatory milestone, and support commercial launch in 2023 as well as scale additional assays on their ultrasensitive chemistry reagent platform.

Check Out Amplified Sciences’ Dedicated Page

The show never stops. If you missed the opportunity to pitch in March, applications are now open for RESI Boston, June 5-7. Apply to pitch in-person pitch on June 5. RESI Boston June is a hybrid format conference starting with a one day (June 5) in-person conference experience including partnering meeting, investor panels, IPC, workshops and Global Partnering Campaign and Roadshow Preparation classes at The Westin Copley Place in Boston, MA. Followed by two days (June 6-7) of a virtual partnering only event. Pitch applications are accepted on a rolling basis, so get yours in today!

Apply-for-the-IPC

Application deadline is Friday, April 21.

Want to be part of RESI Boston June? Register now to save $500 on super early bird rates by April 7. RESI also provides sponsorship and exhibition opportunities to help you increase your brand visibility at RESI Boston June or any future RESI conferences, contact us to learn more.

RESI-Boston-2023-June-1100px

Digital RESI March – A Tailor Made Conference for Early-Stage Life Science Fundraising Startups

9 Mar

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

Digital RESI March is merely days away, and It’s never too late for you to catch this terrific opportunity to meet with 250+ early-stage investors and licensing partners at a fraction of the overall cost of attending an in-person event. Fundraising is a numbers game and deals can take up to 9-18 months, so meeting with investors frequently can give you a competitive edge. Not only with partnering, in addition digital RESI March is designed with high-quality panels, pitch sessions, and Global Partnering Campaign and Roadshow Preparation Courses.

1:1 Partnering

LSN expects 250+ global investors at digital RESI March seeking new technology assets for their portfolios. LSN’s partnering events are international in scope and include companies across the silos of drugs, devices, diagnostics, digital health and R&D / life science tools. With the most powerful partnering platform RESI can match companies and partners based on stage of development and product fit.

Investor Panels & Workshops

Check out our impressive panels aimed at aiding early-stage CEOs as they navigate the fundraising landscape, while also providing insight for investors and strategic partners into the latest tech and industry developments.

Global Partnering Campaign and Roadshow Preparation Courses

Digital RESI March will feature a novel entrepreneurial education track, the LSN Global Partnering Campaign and Roadshow Preparation course, which will include six classes. This education focus will be for entrepreneurs who are starting to plan for their fundraising and licensing partner search and how LSN can help. An important theme for the education program will concern how to plan and execute a global roadshow efficiently, which can greatly determine an early-stage entity’s success when moving from their regional environment to the global competitive landscape.

Innovator’s Pitch Challenge

34 life science innovators’ representing therapeutics, medical devices, diagnostics, digital health, and R&D / life science tools will be delivering a short pitch followed by a Q&A session with a panel of investors and industry experts. At the meantime, the companies will have a dedicated landing page, including non-confidential materials of their company, that will be showcased to all RESI attendees as a way for participating companies to boost their exposure.

We look forward to seeing you at RESI next week! You can still register for the conference and engage in partnering meetings with attendees of interest, and join our robust program of investor panels, Entrepreneurial Education Courses, and pitch sessions.

RESI-March-Agenda-03092023

RESI-Boston-2023-June-1100px-border

Audience Access Pass – A Runway for Your Fundraising Journey

9 Mar

By Antoinette Lowre, Manager of Business Development, LSN

If you have checked out our lineup of content scheduled for next week but find yourself not ready to start your fundraising round and meet with investors and strategic partnering, consider the Audience Access registration option ($295).

The Audience Access pass allows you to take advantage of LSN’s Global Partnering Campaign and Roadshow Preparation courses, which is built into the agenda for Digital RESI March 14-16. You will also get access to watch all the live investor panels, and entrepreneur workshops, and attend the Innovator’s Pitch Challenge sessions to watch startup CEOs pitch.

The LSN Global Partnering Campaign and Roadshow Preparation course will include 6 classes, 2 per day over the 3 day conference. These courses are focused on where to start with planning and executing a global fundraising campaign and how LSN can help with our vast network of investors.

AAP_March

Another registration option is the RESI Bundle Package. A way to increase your fundraising opportunities and save $1000 to attend both Digital RESI March & RESI June 5-7 in Boston this summer. Check out the RESI Bundle Package options below!

One Ticket for 2 Conferences! 
More investor meetings and more savings with special RESI BUNDLES 
Digital RESI March 14-16
RESIConference.com		 RESI June 5-7
The Westin Copley Place, Boston (June 5)
Virtual Partnering only (June 6-7)
Standard Bundle (March 14-16 & June 5-7) Digital Bundle (March 14-16 & June 6-7)
STARTUP $2,190 $3,190 $1,690 $2,690
SERVICE PROVIDER $2,990 $3,990 $2,290 $2,290
TECH HUB (Including Startup Who’ve Raised Less than $2MM USD ) $1,990 $2,390 $1,390 $2,390
Contact us to discuss further

RESI-Boston-2023-June-1100px-border
RESI-Boston-2023-June-1100px

Innovator’s Pitch Challenge Judges at Digital RESI March 

9 Mar

By Karen Deyo, Director of Investor Research, Israel BD, LSN

The Innovator’s Pitch Challenge (IPC) has become one of the highlights of RESI, where entrepreneurs get a chance to pitch their companies to investors and industry experts, as well as RESI attendees in the audience. Digital RESI March will feature over 34 presenting companies across 9 sessions. Early-stage founders and CEOs will have 4-minutes to pitch and 8-9 minutes to engage in Q&A with the judge’s panel. LSN’s network of investors and strategic partners have actively participated in these sessions from the start and make both the IPC and RESI possible by their willingness to take part and give feedback. Below are the judges taking part in the IPC Q&A panels – thank you all for your participation!

Featured Digital RESI March IPC Judges

Ehi Akhirome
Norwest Venture Partners
Navid Alipour
Analytics Ventures
David Apfel
Johnson & Johnson Innovation

Priya Balachandran
Life Science Angels
Carl Barrett
AstraZeneca
Jay Batchu
Xontogeny

Yael Benvenisti
Mediterranean Tower Ventures
Oded Biran
Individual Angel
Elsa Boukadoum
Biogen

Bettina Ernst
BERNINA BioInvest
David Fogel
Mass Medical Angels
Gita Gupta
NextStep Ventures

Tai Harada
Fast Track Initiative
Z Haroon
Julz Co
Ozan Isinak
Keiretsu Forum

Julia Kaufman
Boehringer Ingelheim Venture Fund
John Kim
Aphelion Capital
Merika Koday
Accelerator Life Science Partners

Will Krawczyk
Banner Venture Group
Cheryl Kuai
Sixty Degree Capital
Carla Lema Tome
Spark Therapeutics

Linda Li
Cleveland Clinic Ventures
Kevin Lin
Transcenta Holding
Fiona Mack
Bayer

Alexander Martynov
Biovision Ventures
Milind Parate
Northwell Ventures
Laura Pedroza
High-Tech GrÜnderfonds

Stefan Pflanz
Boehringer Ingelheim Venture Fund
Armin Rump
Otsuka Pharmaceutical
Diana Saraceni
Panakes Partners

Goslik Schepers
Brandon Capital Partners
Shirin Schneeberger
Apollo Health Ventures
Randy Scott
HealthQuest Capital

Steve Seuntjens
Personal Health Solutions
Jill Sorensen
Medical Technology Enterprise Consortium (MTEC)
Karen Spilizewski
RiverVest Venture Partners

Santosh Vetticaden
NuFund Venture Group
Jingjing Wang
Lightstone Ventures
Aaron Welch
SymBiosis Capital Management

RESI-Boston-2023-June-1100px-border

← Older Entries
Newer Entries →